Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association

Clinical Pharmacology and Therapeutics

Volumn , Issue , 2016, Pages 558-564

  Gagne, J J ^a   Han, X ^b   Hennessy, S ^b   Leonard, C E ^b   Chrischilles, E A ^c   Carnahan, R M ^c   Wang, S V ^a   Fuller, C ^d   Iyer, A ^d   Katcoff, H ^d   Woodworth, T S ^d   Archdeacon, P ^e   Meyer, T E ^e   Schneeweiss, S ^a   Toh, S ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALISKIREN; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LABETALOL; LISINOPRIL; METOPROLOL; MOEXIPRIL; NEBIVOLOL; PERINDOPRIL; PINDOLOL; PROPRANOLOL; QUINAPRIL; RAMIPRIL; TIMOLOL; TRANDOLAPRIL;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROPENSITY SCORE; QUANTITATIVE ANALYSIS; SENTINEL PROPENSITY SCORE MATCHING; SENTINEL SURVEILLANCE;

EID: 84990226922     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.429     Document Type: Article

References (22)

1. Platt, R. et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol. Drug Saf. 21(Suppl 1), 1–8 (2012).
2. Forrow, S. et al. The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program. Pharmacoepidemiol. Drug Saf. 21 (suppl. 1), 12–17 (2012).
3. Carnahan, R.M. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative data: summary of findings and suggestions for future research. Pharmacoepidemiol. Drug Saf. 21 (suppl. 1), 90–99 (2012).
4. Gagne, J.J. et al. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol. Drug Saf. 21 (suppl. 1), 32–40 (2012).
5. Maro, J.C. et al. Design of a national distributed health data network. Ann. Intern. Med. 151, 341–344 (2009).
6. Gagne, J.J. Common models, different approaches. Drug Saf. 38, 683–686 (2015).
7. Xu, Y. et al. A comparative assessment of observational medical outcomes partnership and Mini-Sentinel common data models and analytics: implications for active drug safety surveillance. Drug Saf. 38, 749–765 (2015).
8. Mini-Sentinel Prospective Routine Observational Monitoring Program Tool: Continous and Group Sequential Analysis with Self-control Design Technical Users' Guide version 1.0. 2014.
9. Gagne, J.J., Wang, S.V., Rassen, J.A. & Schneeweiss, S. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiol. Drug Saf. 23, 619–627 (2014).
10. Mini-Sentinel Prospective Routine Observational Monitoring Program Tool: Cohort Matching Technical Users' Guide version 1.0. 2014. (2014).
11. Israili, Z.H. & Hall, W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med. 117, 234–242 (1992).
12. Sabroe, R.A. & Black, A.K. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br. J. Dermatol. 136, 153–158 (1997).
13. Slater, E.E. et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 260, 967–970 (1988).
14. Toh, S. et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch. Intern. Med. 172, 1582–1589 (2012).
15. Miller, D.R. et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51, 1624–1630 (2008).
16. Brown, N.J., Ray, W.A., Snowden, M. & Griffin, M.R. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin. Pharmacol. Ther. 60, 8–13 (1996).
17. Schneeweiss, S. et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am. J. Epidemiol. 154, 854–864 (2001).
18. Pare, G., et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet. Genomics 23, 470–478 (2013).
19. Brown, N.J., Snowden, M. & Griffin, M.R. Recurrent angiotensin-converting enzyme inhibitor—associated angioedema. JAMA 278, 232–233 (1997).
20. Schneeweiss, S. et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am. J. Epidemiol. 154, 854–864 (2001).
21. Gagne, J.J., Glynn, R.J., Avorn, J., Levin, R. & Schneeweiss, S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J. Clin. Epidemiol. 64, 749–759 (2011).
22. McGraw, D., Rosati, K. & Evans, B. A policy framework for public health uses of electronic health data. Pharmacoepidemiol. Drug Saf. 21(Suppl 1), 18–22 (2012).